Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357242 | 1.00 | HSD17B10 (0.50) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL9893215 | 1.00 | HSD17B10 (0.50) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL10347006 | 0.96 | HSD17B10 (0.46) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL29484187 | 0.95 | HSD17B10 (0.52) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL6176907 | 0.90 | HSD17B10 (0.44) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL18206674 | 0.87 | HSD17B10 (0.44) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL18206675 | 0.87 | HSD17B10 (0.44) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL19658258 | 0.84 | HSD17B10 (0.42) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL21049847 | 0.84 | HSD17B10 (0.42) | HSD17B10EPHX2NPC1UCHL1KLK7 | |
| SCHEMBL19658381 | 0.84 | HSD17B10 (0.42) | HSD17B10EPHX2NPC1UCHL1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112830956-B | Liquid phase synthesis method of palmitoyl tetrapeptide-7 | 山东美欣生物科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| EP-0828767-B1 | MOLECULARLY IMPRINTED BEADED POLYMERS AND STABILIZED SUSPENSION POLYMERIZATION OF THE SAME IN PERFLUOROCARBON LIQUIDS | IGEN INC (US) | 2003-07-30 | — | — | EP | claimed |
| US-5872198-A | MOLECULARLY IMPRINTED POLYMER SUPPORTS CAPABLE OF SEPARATING OR RESOLVING AMINO-ACIDS, AMINO-ACID DERIVATIVES, PHARMACEUTICAL COMPOUNDS AND POLYSACCHARIDES | MOSBACH KLAUS (SE) | 1999-02-16 | — | — | US | claimed |
| EP-0828767-A1 | MOLECULARLY IMPRINTED BEADED POLYMERS AND STABILIZED SUSPENSION POLYMERIZATION OF THE SAME IN PERFLUOROCARBON LIQUIDS | IGEN, INC. (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037527-A1 | MOLECULARLY IMPRINTED BEADED POLYMERS AND STABILIZED SUSPENSION POLYMERIZATION OF THE SAME IN PERFLUOROCARBON LIQUIDS | IGEN, INC. (US) | 1996-11-28 | — | — | WO | claimed |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-10-16 | — | — | US | disclosed |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-07-17 | — | — | US | disclosed |
| US-5821311-A | Stabilizers, polymers, and emulsions useful for molecular imprinting technology | MOSBACH KLAUS (CH) | 1998-10-13 | — | — | US | disclosed |
| EP-0838471-A1 | PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0828767-A1 | MOLECULARLY IMPRINTED BEADED POLYMERS AND STABILIZED SUSPENSION POLYMERIZATION OF THE SAME IN PERFLUOROCARBON LIQUIDS | IGEN, INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037527-A1 | MOLECULARLY IMPRINTED BEADED POLYMERS AND STABILIZED SUSPENSION POLYMERIZATION OF THE SAME IN PERFLUOROCARBON LIQUIDS | IGEN, INC. (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0480044-A1 | NOVEL 4H-3,1-BENZOXAZIN-4-ONE DERIVATIVE | Japan Tobacco Inc. (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-4775743-A | ANTIAGGLOMERANTS | GREEN CROSS CORPORATION (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0214659-A2 | Peptide derivatives, process for the production thereof and pharmaceutical compositions containing same | GREEN CROSS CORPORATION (JP) | 1987-03-18 | — | — | EP | disclosed |
| EP-0080305-A1 | Antiviral 2'-deoxyuridines, their preparation and use | BEECHAM GROUP PLC (GB) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | HSD17B10 342/4885EPHX2 1025/4885NPC1 1564/4885 |
| US-20250320233-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ARG1, ARG2, PRMT1 | HSD17B10 1022/4885EPHX2 2422/4885NPC1 653/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HSD17B10 323/4885EPHX2 965/4885NPC1 1610/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HSD17B10 687/4885EPHX2 299/4885NPC1 3564/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HSD17B10 687/4885EPHX2 299/4885NPC1 3564/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | HSD17B10 3090/4885EPHX2 3452/4885NPC1 2524/4885 |
| US-20250228855-A1 | PYRAZINAMIDE COMPOUNDS | PC, GOT2, PCK2 | HSD17B10 2116/4885EPHX2 3268/4885NPC1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.